Jacobs Levy Equity Management
ACUR

Jacobs Levy Equity Management’s Acura Pharmaceuticals ACUR Stock Holding History

Jacobs Levy Equity Management’s Portfolio ACUR Stock Details ACUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-48,756
Closed -$115K – 926
2015
Q3 		$115K Buy
48,756
+279
+0.6% +$949 ﹤0.01% 753
2015
Q2 		$239K Buy
48,477
+40,537
+511% +$168K ﹤0.01% 697
2015
Q1 		$31K Buy
+7,940
New +$25.3K ﹤0.01% 772

Other funds holding ACUR

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.61B AUM 19.97% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jacobs Levy Equity Management's ACUR Position: Q4 2015 in Review

Jacobs Levy Equity Management sold out of Acura Pharmaceuticals (ACUR) in Q4 2015, closing a stake of 48,756 shares — an estimated $115K sold.

Jacobs Levy Equity Management first reported a position in ACUR in Q1 2015 and held it in 3 quarters. The position peaked at $239K in Q2 2015. 22 funds tracked by Wall St. Rank hold ACUR as of Q4 2015.

  • Jacobs Levy Equity Management reported no remaining Acura Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 48,756 Acura Pharmaceuticals shares in Q4 2015, an estimated $115K.
  • Jacobs Levy Equity Management first reported a position in Acura Pharmaceuticals in Q1 2015 and held it in 3 quarters.
  • Jacobs Levy Equity Management's Acura Pharmaceuticals position peaked at $239K in Q2 2015.
  • 22 funds tracked by Wall St. Rank held Acura Pharmaceuticals as of Q4 2015.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2015, filed 16 Feb 2016.